A61K 47/6867
The tumour determinant being from a cell of a blood cancer
Official title: {the tumour determinant being from a cell of a blood cancer}
A61K47/6867 (The tumour determinant being from a cell of a blood cancer) appears on 374 US grants and 631 published applications in this corpus.
Search patents in A61K- Granted patents
- 374
- Published applications
- 631
- Assignees
- 187
- Inventors
- 878
- Latest grant
- 1 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 1 | 0 |
| 1990 | 2 | 0 |
| 1991 | 1 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 2 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 2 | 0 |
| 2002 | 2 | 4 |
| 2003 | 2 | 4 |
| 2004 | 0 | 6 |
| 2005 | 1 | 4 |
| 2006 | 2 | 5 |
| 2007 | 2 | 7 |
| 2008 | 3 | 8 |
| 2009 | 6 | 8 |
| 2010 | 5 | 9 |
| 2011 | 5 | 16 |
| 2012 | 7 | 13 |
| 2013 | 13 | 11 |
| 2014 | 15 | 41 |
| 2015 | 20 | 32 |
| 2016 | 36 | 52 |
| 2017 | 29 | 65 |
| 2018 | 28 | 47 |
| 2019 | 47 | 53 |
| 2020 | 23 | 37 |
| 2021 | 21 | 36 |
| 2022 | 25 | 40 |
| 2023 | 25 | 33 |
| 2024 | 22 | 43 |
| 2025 | 18 | 31 |
| 2026 | 7 | 26 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Anti-CD45 antibody drug conjugates and uses thereof1 Sep 2026US 12,723,097 B2Regeneron Pharmaceuticals, Inc.
- CD33 antibodies16 Jun 2026US 12,655,216 B2University of Florida Research Foundation, Inc.
- Amatoxin antibody-drug conjugates and uses thereof7 Apr 2026US 12,595,284 B2Heidelberg Pharma Research GmbH
- CD37-binding molecules immunoconjugates thereof24 Feb 2026US 12,559,566 B2Debiopharm International S.A.
- Targeted amatoxin conjugate for the treatment of solid tumors10 Feb 2026US 12,544,419 B2Heidelberg Pharma Research GmbH
- Use of anti-cd20 antibody drug conjugate in preparation of drug for treating non-hodgkin lymphoma20 Aug 2026US 2026/0241027 A1Zhejiang Teruisi Pharmaceutical Inc.
- Anti-cd180 binding molecules and uses thereof13 Aug 2026US 2026/0232824 A1Champions Oncology, Inc.
- Amatoxin antibody-drug conjugates and uses thereof13 Aug 2026US 2026/0234192 A1Heidelberg Pharma Research GmbH
- Ecteinascidin derivative antibody drug conjugates6 Aug 2026US 2026/0224720 A1Adcytherix SAS
- Herboxidiene antibody-drug conjugates and methods of use6 Aug 2026US 2026/0224730 A1Eisai R&D Management Co., Ltd.
Most cited
By later US patents
- Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells304US 5,789,554 AImmunomedics, Inc. · 1998
- Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease256US 7,659,241 B2Seattle Genetics, Inc. · 2010
- Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells237US 6,187,287 B1Immunomedics, Inc. · 2001
- Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease129US 7,829,531 B2Seattle Genetics, Inc. · 2010
- Camptothecin-binding moiety conjugates110US 7,591,994 B2Immunomedics, Inc. · 2009